We are live on ! Find out more
EC

EcoR1 Capital Portfolio holdings

AUM $2.36B
1-Year Est. Return 204.53%
This Fund
S&P 500
This Quarter Est. Return
+0.5%
1 Year Est. Return
+204.53%
3 Year Est. Return
+306.25%
5 Year Est. Return
+490.45%
10 Year Est. Return
+14,115.48%
AUM
$3.29B
AUM Growth
-$103M
Cap. Flow
+$24.5M
Cap. Flow %
0.75%
Top 10 Hldgs %
70.15%
Holding
85
New
9
Increased
10
Reduced
4
Closed
19

Top Buys

Rank Stock Value
1
RVMD icon
Revolution Medicines
RVMD
+$56.5M
2
ACET icon
Adicet Bio
ACET
+$55.5M
3
ZYME icon
Zymeworks
ZYME
+$53.2M
4
NGM
NGM Biopharmaceuticals, Inc. Common Stock
NGM
+$36.9M
5
DYN icon
Dyne Therapeutics
DYN
+$26.9M

Top Sells

Rank Stock Value
1
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$70.9M
2
GOSS icon
Gossamer Bio
GOSS
+$49.8M
3
RNAM
Avidity Biosciences
RNAM
+$47.3M
4
SGEN
Seagen Inc. Common Stock
SGEN
+$39.1M
5
DSGN icon
Design Therapeutics
DSGN
+$22.1M

Sector Composition

Rank Sector Weight
1 Healthcare 99.78%
2 Financials 0.11%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RETA
76
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
– –
-38,467
Closed -$967K
OMEG
77
DELISTED
Omega Alpha SPAC Class A Ordinary Shares
OMEG
– –
-50,000
Closed -$497K
AKUS
78
DELISTED
Akouos Inc
AKUS
– –
-1,975,984
Closed -$13.4M
JYAC
79
DELISTED
Jiya Acquisition Corp. Class A Common Stock
JYAC
– –
-500,000
Closed -$4.99M
FLAC
80
DELISTED
Frazier Lifesciences Acquisition Corporation Class A Ordinary Shares
FLAC
– –
-487,615
Closed -$4.86M
FLACW
81
DELISTED
Frazier Lifesciences Acquisition Corporation Warrant
FLACW
– –
-66,665
Closed -$665K
BLSA
82
DELISTED
BCLS Acquisition Corp. Class A Ordinary Shares
BLSA
– –
-200,000
Closed -$2M
TMPMW
83
DELISTED
Turmeric Acquisition Corp. Warrant
TMPMW
– –
-33,333
Closed -$333K
TMPM
84
DELISTED
Turmeric Acquisition Corp. Class A Ordinary Shares
TMPM
– –
-100,000
Closed -$1M
FVAM
85
DELISTED
5:01 Acquisition Corp
FVAM
– –
-200,000
Closed -$2M
1 2 3
4

Similar funds

HFM
Harvest Fund Management Beijing, China $2.35B AUM 49.85% 1-Year Est. Return
CC
Capital Counsel New York $2.35B AUM 21.34% 1-Year Est. Return
SCA
STALEY CAPITAL ADVISERS Pittsburgh, Pennsylvania $2.36B AUM 23.72% 1-Year Est. Return
ROIC
Route One Investment Company San Francisco, California $2.35B AUM 11.7% 1-Year Est. Return
BJL
Brighton Jones LLC Seattle, Washington $2.37B AUM 16.36% 1-Year Est. Return
G
GenTrust Miami, Florida $2.34B AUM 18.43% 1-Year Est. Return
MC
Moors & Cabot Boston, Massachusetts $2.34B AUM 30.42% 1-Year Est. Return
CIP
Cornerstone Investment Partners Atlanta, Georgia $2.38B AUM 32.49% 1-Year Est. Return

EcoR1 Capital's Q4 2022 Portfolio in Review

As of Q4 2022, EcoR1 Capital held 85 positions worth $3.29B, down 3% from $3.39B the previous quarter. Its ten largest holdings account for 70% of the portfolio.

EcoR1 Capital's Q4 2022 filing shows 9 new, 10 increased, 4 reduced and 19 closed positions. Its largest new stake was Adicet Bio: 222,544 shares worth $31.8M. The largest sale was Mirati Therapeutics, Inc. Common Stock, an estimated $70.9M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 99% a quarter earlier, followed by Financials.

  • EcoR1 Capital's largest Q4 2022 buy was Adicet Bio: 222,544 shares worth $31.8M.
  • EcoR1 Capital added most to Revolution Medicines in Q4 2022, an estimated $56.5M increase.
  • EcoR1 Capital's biggest Q4 2022 reduction was Design Therapeutics, cutting an estimated $22.1M.
  • EcoR1 Capital fully exited Mirati Therapeutics, Inc. Common Stock in Q4 2022, selling an estimated $70.9M.
  • EcoR1 Capital's ten largest holdings make up 70% of its $3.29B portfolio in Q4 2022.
  • EcoR1 Capital opened 9 new positions and closed 19 in Q4 2022.
  • EcoR1 Capital's portfolio value fell 3% quarter-over-quarter to $3.29B.

Based on EcoR1 Capital's 13F filing for Q4 2022, filed 14 Feb 2023.